AtriCure, Inc. (ATRC)
NASDAQ: ATRC · Real-Time Price · USD
32.75
-1.28 (-3.76%)
At close: Nov 4, 2025, 4:00 PM EST
32.43
-0.32 (-0.98%)
Pre-market: Nov 5, 2025, 5:36 AM EST
AtriCure Market Cap
AtriCure has a market cap or net worth of $1.63 billion as of November 5, 2025. Its market cap has increased by 17.03% in one year.
Market Cap
1.63B
Enterprise Value
1.56B
1-Year Change
17.03%
Ranking
Category
Stock Price
$32.75
Market Cap Chart
Since August 5, 2005, AtriCure's market cap has increased from $167.60M to $1.63B, an increase of 871.50%. That is a compound annual growth rate of 11.88%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 3, 2025 | 1.69B | 13.56% |
| Dec 31, 2024 | 1.49B | -11.92% |
| Dec 29, 2023 | 1.69B | -18.05% |
| Dec 30, 2022 | 2.06B | -35.37% |
| Dec 31, 2021 | 3.19B | 27.42% |
| Dec 31, 2020 | 2.51B | 94.93% |
| Dec 31, 2019 | 1.29B | 9.07% |
| Dec 31, 2018 | 1.18B | 87.48% |
| Dec 29, 2017 | 628.80M | -3.34% |
| Dec 30, 2016 | 650.50M | -10.02% |
| Dec 31, 2015 | 722.90M | 31.84% |
| Dec 31, 2014 | 548.30M | 39.66% |
| Dec 31, 2013 | 392.60M | 241.09% |
| Dec 31, 2012 | 115.10M | -36.16% |
| Dec 30, 2011 | 180.30M | 12.62% |
| Dec 31, 2010 | 160.10M | 73.08% |
| Dec 31, 2009 | 92.50M | 192.72% |
| Dec 31, 2008 | 31.60M | -82.95% |
| Dec 31, 2007 | 185.30M | 70.16% |
| Dec 29, 2006 | 108.90M | -15.25% |
| Dec 30, 2005 | 128.50M | -23.33% |
| Aug 5, 2005 | 167.60M | - |
View and export this data all the way back to 2005. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 811.99B |
| Johnson & Johnson | 450.20B |
| AbbVie | 381.38B |
| UnitedHealth Group | 299.68B |
| AstraZeneca | 253.45B |
| Novartis AG | 240.68B |
| Abbott Laboratories | 218.75B |
| Novo Nordisk | 215.64B |